Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Novel targets for the treatment of autosomal dominant polycystic kidney disease Belibi FA; Edelstein CLExpert Opin Investig Drugs 2010[Mar]; 19 (3): 315-28IMPORTANCE OF THE FIELD: Autosomal dominant (AD) polycystic kidney disease (PKD) is the most common life-threatening hereditary disorder. There is currently no therapy that slows or prevents cyst formation and kidney enlargement in humans. An increasing number of animal studies have advanced our understanding of molecular and cellular targets of PKD. AREAS COVERED IN THE REVIEW: The purpose of this review is to summarize the molecular and cellular targets involved in cystogenesis and to update on the promising therapies that are being developed and tested based on knowledge of these molecular and cellular targets. WHAT THE READER WILL GAIN: Insight into the pathogenesis of PKD and how a better understanding of the pathogenesis of PKD has led to the development of potential therapies to inhibit cyst formation and/or growth and improve kidney function. TAKE HOME MESSAGE: The results of animal studies in PKD have led to the development of clinical trials testing potential new therapies to reduce cyst formation and/or growth. A vasopressin V2 receptor antagonist, mTOR inhibitors, blockade of the renin-angiotensin system and statins that reduce cyst formation and improve renal function in animal models of PKD are being tested in interventional studies in humans.|*Drug Delivery Systems[MESH]|*Drug Design[MESH]|Animals[MESH]|Antidiuretic Hormone Receptor Antagonists[MESH]|Clinical Trials as Topic[MESH]|Disease Models, Animal[MESH]|Humans[MESH]|Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology[MESH]|Intracellular Signaling Peptides and Proteins/antagonists & inhibitors[MESH]|Polycystic Kidney, Autosomal Dominant/*drug therapy/physiopathology[MESH]|Protein Serine-Threonine Kinases/antagonists & inhibitors[MESH]|Renin-Angiotensin System/drug effects[MESH]|TOR Serine-Threonine Kinases[MESH] |